{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T17:03:12Z","timestamp":1773248592537,"version":"3.50.1"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2018,1,25]],"date-time":"2018-01-25T00:00:00Z","timestamp":1516838400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006044","name":"Astellas Pharma Europe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006044","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11,1]]},"DOI":"10.1093\/pm\/pnx338","type":"journal-article","created":{"date-parts":[[2017,12,22]],"date-time":"2017-12-22T05:06:41Z","timestamp":1513919201000},"page":"2246-2255","source":"Crossref","is-referenced-by-count":3,"title":["A Phase I, Randomized, Double-Blind, Laser-Evoked Potential Study to Evaluate the Analgesic\/Antihyperalgesic Effect of ASP9226, a State-Dependent N-Type Voltage-Gated Calcium Channel Inhibitor, in Healthy Male Subjects"],"prefix":"10.1093","volume":"19","author":[{"given":"Klaus","family":"Schaffler","sequence":"first","affiliation":[{"name":"HPR (Human Pharmacodynamic Research) Dr. Schaffler GmbH, Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weizhong","family":"He","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development, Northbrook, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Passier","sequence":"additional","affiliation":[{"name":"Astellas Pharma Europe B.V., Leiden, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Tracy","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development, Northbrook, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allam","family":"Fakhoury","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development, Northbrook, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Paul","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development, Northbrook, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,1,25]]},"reference":[{"issue":"5","key":"key\n\t\t\t\t2018110507562174300_pnx338-B1","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/j.1476-5381.2012.02082.x","article-title":"Targeting voltage-gated calcium channels: Developments in peptide and small-molecule inhibitors for the treatment of neuropathic pain","volume":"167","author":"Vink","year":"2012","journal-title":"Br J Pharmacol"},{"key":"key\n\t\t\t\t2018110507562174300_pnx338-B2","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1523\/JNEUROSCI.15-04-02995.1995","article-title":"Pharmacological dissection of multiple types of Ca2+ channel currents in rat cerebellar granule neurons","volume":"15","author":"Randall","year":"1995","journal-title":"J Neurosci"},{"issue":"1","key":"key\n\t\t\t\t2018110507562174300_pnx338-B3","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2174\/1570159X1201140117162802","article-title":"Pregabalin in neuropathic pain: Evidences and possible mechanisms","volume":"12","author":"Verma","year":"2014","journal-title":"Curr Neuropharmacol"},{"issue":"3","key":"key\n\t\t\t\t2018110507562174300_pnx338-B4","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.pain.2007.08.033","article-title":"Pharmacologic management of neuropathic pain: Evidence-based recommendations","volume":"132","author":"Dworkin","year":"2007","journal-title":"Pain"},{"issue":"5","key":"key\n\t\t\t\t2018110507562174300_pnx338-B5","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1097\/00000542-200211000-00033","article-title":"Gabapentin and pregabalin can interact synergistically with naproxen to produce antihyperalgesia","volume":"97","author":"Hurley","year":"2002","journal-title":"Anesthesiology"},{"issue":"46","key":"key\n\t\t\t\t2018110507562174300_pnx338-B6","doi-asserted-by":"crossref","first-page":"17537","DOI":"10.1073\/pnas.0409066103","article-title":"Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin","volume":"103","author":"Field","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1\u20133","key":"key\n\t\t\t\t2018110507562174300_pnx338-B7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ejphar.2009.01.014","article-title":"Oral pregabalin reverses cold allodynia in two distinct models of peripheral neuropathic pain","volume":"605","author":"Gustafsson","year":"2009","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"key\n\t\t\t\t2018110507562174300_pnx338-B8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1464-5491.2010.03152.x","article-title":"Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: A 14 week, randomized, double-blind, placebo-controlled trial","volume":"28","author":"Satoh","year":"2011","journal-title":"Diabet Med"},{"issue":"3","key":"key\n\t\t\t\t2018110507562174300_pnx338-B9","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/AJP.0b013e3181fe13f6","article-title":"Pregabalin for peripheral neuropathic pain: A multicenter, enriched enrollment randomized withdrawal placebo-controlled trial","volume":"27","author":"Gilron","year":"2011","journal-title":"Clin J Pain"},{"issue":"8","key":"key\n\t\t\t\t2018110507562174300_pnx338-B10","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1097\/AJP.0b013e31823f9e64","article-title":"The pain quality response profile of pregabalin in the treatment of neuropathic pain","volume":"28","author":"Jensen","year":"2012","journal-title":"Clin J Pain"},{"issue":"8","key":"key\n\t\t\t\t2018110507562174300_pnx338-B11","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1212\/01.WNL.0000055433.55136.55","article-title":"Pregabalin for the treatment of postherpetic neuralgia: A randomized, placebo-controlled trial","volume":"60","author":"Dworkin","year":"2003","journal-title":"Neurology"},{"issue":"7","key":"key\n\t\t\t\t2018110507562174300_pnx338-B12","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1111\/j.1526-4637.2011.01162.x","article-title":"Replacement of gabapentin with pregabalin in postherpetic neuralgia therapy","volume":"12","author":"Ifuku","year":"2011","journal-title":"Pain Med"},{"issue":"7","key":"key\n\t\t\t\t2018110507562174300_pnx338-B13","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1111\/bcp.13247","article-title":"Investigation of the predictive validity of laser-EPs in normal, UVB-inflamed and capsaicin-irritated skin with four analgesic compounds in healthy volunteers","volume":"83","author":"Schaffler","year":"2017","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"key\n\t\t\t\t2018110507562174300_pnx338-B14","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/2042098613505614","article-title":"Pregabalin: Latest safety evidence and clinical implications for the management of neuropathic pain","volume":"5","author":"Toth","year":"2014","journal-title":"Ther Adv Drug Saf"},{"issue":"3","key":"key\n\t\t\t\t2018110507562174300_pnx338-B15","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1124\/pr.111.005447","article-title":"Human experimental pain models for assessing the therapeutic efficacy of analgesic drugs","volume":"64","author":"Olesen","year":"2012","journal-title":"Pharmacol Rev"},{"issue":"2","key":"key\n\t\t\t\t2018110507562174300_pnx338-B16","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1365-2125.2012.04377.x","article-title":"An oral TRPV1 antagonist attenuates laser radiant-heat-evoked potentials and pain ratings from UV(B)-inflamed and normal skin","volume":"75","author":"Schaffler","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"key\n\t\t\t\t2018110507562174300_pnx338-B17","first-page":"148","article-title":"The effect of topical capsaicin-induced sensitization on heat-evoked cutaneous vasomotor responses","volume":"5","author":"Nielsen","year":"2013","journal-title":"Int J Physiol Pathophysiol Pharmacol"},{"issue":"3","key":"key\n\t\t\t\t2018110507562174300_pnx338-B18","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/01.j.pain.0000460328.10515.c9","article-title":"Pattern of neuropathic pain induced by topical capsaicin application in healthy subjects","volume":"156","author":"Lotsch","year":"2015","journal-title":"Pain"},{"issue":"1","key":"key\n\t\t\t\t2018110507562174300_pnx338-B19","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.brainresrev.2008.12.016","article-title":"Predicting therapeutic efficacy\u2014experimental pain in human subjects","volume":"60","author":"Chizh","year":"2009","journal-title":"Brain Res Rev"},{"issue":"8","key":"key\n\t\t\t\t2018110507562174300_pnx338-B20","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1016\/j.pain.2012.04.018","article-title":"Dose-response relationship after single oral dose administrations of morphine and oxycodone using laser-evoked potentials on UVB- and capsaicin-irritated skin in healthy male subjects","volume":"153","author":"Hoeben","year":"2012","journal-title":"Pain"},{"issue":"4","key":"key\n\t\t\t\t2018110507562174300_pnx338-B21","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/00126839-200506040-00001","article-title":"Comparison of the analgesic effects of a fixed-dose combination of orphenadrine and diclofenac (Neodolpasse) with its single active ingredients diclofenac and orphenadrine: A placebo-controlled study using laser-induced somatosensory-evoked potentials from capsaicin-induced hyperalgesic human skin","volume":"6","author":"Schaffler","year":"2005","journal-title":"Drugs R D"},{"issue":"10","key":"key\n\t\t\t\t2018110507562174300_pnx338-B22","first-page":"673","article-title":"Analgesic effects of low-dose intravenous orphenadrine in the state of capsaicin hyperalgesia. A randomised, placebo-controlled, double-blind cross-over study using laser somatosensory evoked potentials obtained from capsaicin-irritated skin in healthy volunteers","volume":"54","author":"Schaffler","year":"2004","journal-title":"Arzneimittelforschung"},{"key":"key\n\t\t\t\t2018110507562174300_pnx338-B23","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2147\/DMSO.S24825","article-title":"Guidelines in the management of diabetic nerve pain: Clinical utility of pregabalin","volume":"6","author":"Vinik","year":"2013","journal-title":"Diabetes Metab Syndr Obes"}],"container-title":["Pain Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/painmedicine\/article-pdf\/19\/11\/2246\/26338997\/pnx338.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T19:23:50Z","timestamp":1589829830000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/painmedicine\/article\/19\/11\/2246\/4825325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,25]]},"references-count":23,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2018,1,25]]},"published-print":{"date-parts":[[2018,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/pm\/pnx338","relation":{},"ISSN":["1526-2375","1526-4637"],"issn-type":[{"value":"1526-2375","type":"print"},{"value":"1526-4637","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,11]]},"published":{"date-parts":[[2018,1,25]]}}}